Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options
-
CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025
-
CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
-
CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
-
CARGO Therapeutics to Participate in Upcoming Investor Conferences
-
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma
-
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
-
CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director
-
CARGO Therapeutics to Participate in Upcoming Investor Conferences
-
CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing